Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Key issues in end point selection for heart failure trials: composite end points.

James D Neaton1, Gerry Gray, Bram D Zuckerman

  • 1Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota 55414, USA.

Journal of Cardiac Failure
|October 19, 2005
PubMed
Summary

Composite outcomes in heart failure trials offer higher event rates and smaller sample sizes. However, careful interpretation is needed due to potential variations in treatment effects among components.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vagal Nerve Stimulation in Patients With Heart Failure and Reduced Ejection Fraction: The ANTHEM-HFrEF Trial.

Journal of the American College of Cardiology·2026
Same author

Association of the Timing of Acute Declines in Kidney Function in Acute Heart Failure With Cardiovascular and Kidney Outcomes.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same author

Subgroups and Special Populations in Heart Failure Clinical Trials: Insights From the HFC-ARC Expert Consensus Panel.

JACC. Heart failure·2026
Same author

Demystifying the Impact of Kidney Risk on Finerenone Effects in Heart Failure.

JACC. Heart failure·2025
Same author

Cyclodialysis Surgery for Glaucoma Management: A Systematic Review and Meta-Analysis of 100 Years of Clinical Evidence.

Clinical ophthalmology (Auckland, N.Z.)·2025
Same author

Thresholds of Kidney Function Decline and Congestion Status and Their Relation with Outcomes among Discharged Heart Failure Patients.

Clinical journal of the American Society of Nephrology : CJASN·2025

Area of Science:

  • Cardiology
  • Clinical Trials
  • Biostatistics

Background:

  • Composite outcomes are frequently employed in heart failure clinical trials.
  • This article critically examines the benefits and drawbacks of using composite outcomes.
  • Guidelines for reporting composite outcomes are proposed, with illustrative examples.

Purpose of the Study:

  • To discuss the advantages and disadvantages of composite outcomes in heart failure trials.
  • To provide recommendations for the reporting of composite outcomes.
  • To illustrate key considerations with practical examples.

Main Methods:

  • A workshop was convened by the Heart Failure Society of America and the US Food and Drug Administration in April 2004.
  • Panel discussions focused on the application of composite outcomes in heart failure research.

Related Experiment Videos

  • Literature review and expert consensus informed the discussion.

    • Main Results:

    • Composite outcomes increase event rates and can reduce sample size if treatment effects are similar across components.
    • Interpretation challenges arise when treatment effects vary among components or disproportionately affect less severe events.
    • Focusing only on the first event in composite outcomes can lead to significant information loss.

    Conclusions:

    • Composite endpoints should be utilized with caution in heart failure trials.
    • Further research is required for optimal weighting of composite outcome components.
    • Exploring methods to incorporate the entire patient event history is essential for more comprehensive trial analysis.